Product ID: SQMIG45A2208
Hemodynamic Monitoring Systems Market Size, Share, Growth Analysis, By End users(Hospitals, Clinics), By Type(Invasive, Non-invasive and Others), By Product(Monitors and Disposables) - Industry Forecast 2024-2031
Report ID:
SQMIG45A2208 |
Region:
Global |
Published Date: April, 2024
Pages:
197
|
Tables:
88 |
Figures:
73
Hemodynamic Monitoring Systems Market News
- Noninvasix disclosed in February 2022 that its LIVOx Central Venous Oxygenation Monitor had achieved Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). This designation underscores the device's pivotal role in providing non-invasive, real-time, continuous, or spot monitoring of central venous oxygen saturation (ScvO2) in adults at risk of septic shock. The Breakthrough Device Designation reflects the FDA's recognition of the monitor's potential to address critical medical needs, emphasizing its importance in advancing patient care.
- In January 2022, Sensydia, a pioneering player in rapid, non-invasive measurement of critical cardiac function, revealed that its Cardia Performance System (CPSTM) had earned Breakthrough Device Designation from the United States Food and Drug Administration (FDA). This designation positions the CPSTM as an innovative and essential device, signifying its capability to address critical cardiac function swiftly and non-invasively. Both breakthrough designations highlight the FDA's acknowledgment of these advanced medical technologies, showcasing their potential to significantly impact patient outcomes and mark substantial advancements in the field of non-invasive medical monitoring.
Hemodynamic Monitoring Systems Market Report Snapshots
Want to customize this report?
Our industry expert will work with you to provide you with customized data in a short amount of time.
REQUEST FREE CUSTOMIZATION
USA (+1) 351-333-4748
